What's Happening?
Invivoscribe has announced the launch of the PrepQuant System, an integrated sample preparation platform designed to standardize and streamline pre-analytical workflows in molecular testing. Developed in collaboration with Hitachi High-Tech Corporation,
the system integrates nucleic acid extraction, concentration, and quantification into a single automated instrument. This innovation aims to reduce costs, sample variability, and lab space requirements while optimizing test results. The system is assay agnostic and supports various testing methods, including next-generation sequencing and digital PCR.
Why It's Important?
The introduction of the PrepQuant System represents a significant advancement in precision diagnostics, particularly in the field of molecular testing. By standardizing pre-analytical workflows, the system addresses a critical source of variability that can affect the accuracy and reliability of test results. This is especially important in precision medicine, where consistent and high-quality data are essential for effective diagnosis and treatment. The system's ability to reduce operational costs and improve efficiency could benefit laboratories and healthcare providers, ultimately enhancing patient care.
What's Next?
Invivoscribe plans to officially unveil the PrepQuant System at the American Association for Cancer Research Annual Meeting. The company anticipates commercial shipments in North America by August 2026, with European availability in January 2027. Further development of the system is underway to accommodate additional specimen types, and new kit releases are expected by the end of 2026. The launch of the PrepQuant System may prompt other companies in the diagnostics industry to explore similar innovations to improve testing efficiency and accuracy.
